KRT9 (Keratin, type I cytoskeletal 9) variants and mutations
KRT9 (also known as Keratin, type I cytoskeletal 9) is a human protein-coding gene encoding a keratin, type I cytoskeletal 9 protein. It is highly enriched in palm and sole epidermis and reinforces keratinocytes exposed to repetitive mechanical load. Dominant pathogenic variants cause epidermolytic palmoplantar keratoderma with thickening and fragility of palms and soles. This analysis covers 1,176 KRT9 variants and mutations. Of these, 80% have computational variant effect predictions. Disease context includes epidermolytic palmoplantar keratoderma, 1, palmoplantar keratoderma, epidermolytic, and Localized epidermolytic hyperkeratosis. Example KRT9 variants include S2N, C3S, and C3Y.
Variant analysis overview
- Gene: KRT9
- Protein: Keratin, type I cytoskeletal 9
- UniProt accession: P35527
- Organism: Homo sapiens
- Variants analyzed: 1176
- Variant scope: all variants
- Completed: 2026-08-22
Variant and mutation evidence
- Variant composition: 846 unspecified-consequence records; 1 stop lost; 133 synonymous variants; 149 missense variants; 18 in-frame deletions; 11 stop-gained variants; 15 frameshift variants; 4 in-frame insertions; 1 splice-region variants
- Prediction scores: 940 variants have prediction scores (80% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: epidermolytic palmoplantar keratoderma, 1, palmoplantar keratoderma, epidermolytic, Localized epidermolytic hyperkeratosis, Palmoplantar keratoderma, hereditary disease, hereditary palmoplantar keratoderma, Familial prostate cancer, prostate cancer, erythrokeratodermia variabilis, Non-epidermolytic palmoplantar keratoderma, lamellar ichthyosis, pachyonychia congenita.
Protein structure and variant hotspots
- Protein features: 1 domains; 2 post-translational modification sites.
- Structural context: 527 variants have structural context.
- PTM context: 4 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable KRT9 variants
Examples include S2N, C3S, C3Y, R4K, Q5E, Q5P, Q5R, F6L. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- S2N (p.Ser2Asn), TOPMed rs1907108401, REVEL 0.13, CADD 17.40, Uncertain significance, Inborn genetic diseases
- C3S (p.Cys3Ser), ExAC rs764394233, gnomAD rs764394233, REVEL 0.27, CADD 16.80
- C3Y (p.Cys3Tyr), ExAC rs764394233, gnomAD rs764394233, REVEL 0.29, CADD 17.10
- R4K (p.Arg4Lys), gnomAD rs1907108198, REVEL 0.38, CADD 20.60
- Q5E (p.Gln5Glu), gnomAD rs1186331728, REVEL 0.37, CADD 22.00
- Q5P (p.Gln5Pro), ExAC rs758757943, gnomAD rs758757943, REVEL 0.41, CADD 23.20
- Q5R (p.Gln5Arg), ExAC rs758757943, gnomAD rs758757943, REVEL 0.27, CADD 22.80
- F6L (p.Phe6Leu), rs200697505, ClinGen CA8562358, ClinVar RCV004414644, 1000Genomes rs200697505, REVEL 0.14, CADD 11.00, Uncertain significance, Inborn genetic diseases
- S7F (p.Ser7Phe), TOPMed rs1248835319, REVEL 0.33, CADD 15.40
- S8L (p.Ser8Leu), rs759755813, ClinGen CA8562356, ClinVar RCV002854757, ClinVar RCV006473035, REVEL 0.29, CADD 2.58, Uncertain significance, Inborn genetic diseases; not provided
- S8W (p.Ser8Trp), ExAC rs759755813, TOPMed rs759755813, gnomAD rs759755813, Uncertain significance
- S9F (p.Ser9Phe), ExAC rs776856368, gnomAD rs776856368, REVEL 0.32, CADD 19.90
- Y10H (p.Tyr10His), Ensembl rs1907107044, REVEL 0.29, CADD 9.34
- L11* (p.Leu11Ter), gnomAD rs1263741776, CADD 24.90
- L11F (p.Leu11Phe), NCI-TCGA Cosmic COSV5585, REVEL 0.17, CADD 7.32, Variant assessed as somatic; moderate impact.
- S12G (p.Ser12Gly), TOPMed rs1162959947, gnomAD rs1162959947, REVEL 0.24, CADD 6.05
- S12R (p.Ser12Arg), TOPMed rs1162959947, gnomAD rs1162959947, REVEL 0.32, CADD 5.24
- R13C (p.Arg13Cys), ExAC rs773447868, TOPMed rs773447868, gnomAD rs773447868, REVEL 0.36, CADD 10.30
- R13H (p.Arg13His), rs749091007, ClinGen CA8562349, ClinVar RCV002009586, ClinVar RCV005350866, REVEL 0.20, CADD 2.05, Uncertain significance, Inborn genetic diseases; not provided
- R13L (p.Arg13Leu), ExAC rs749091007, TOPMed rs749091007, gnomAD rs749091007, REVEL 0.23, CADD 7.15, Uncertain significance, Inborn genetic diseases
- R13P (p.Arg13Pro), ExAC rs749091007, TOPMed rs749091007, gnomAD rs749091007, Uncertain significance
- R13S (p.Arg13Ser), NCI-TCGA Cosmic COSV5585, Variant assessed as somatic; moderate impact.
- S14G (p.Ser14Gly), gnomAD rs1907106567, REVEL 0.17, CADD 3.93
- S14R (p.Ser14Arg), 1000Genomes rs116077803, ESP rs116077803, ExAC rs116077803, TOPMed rs116077803, REVEL 0.32, CADD 17.00, Benign
- G15S (p.Gly15Ser), 1000Genomes rs376253549, ExAC rs376253549, TOPMed rs376253549, gnomAD rs376253549, REVEL 0.20, CADD 1.65
- G16R (p.Gly16Arg), rs780699884, ClinGen CA8562344, ClinVar RCV002697377, ExAC rs780699884, REVEL 0.35, CADD 0.18, Uncertain significance, Inborn genetic diseases
- G16W (p.Gly16Trp), ExAC rs780699884, TOPMed rs780699884, gnomAD rs780699884, REVEL 0.34, CADD 0.04, Uncertain significance
- G17D (p.Gly17Asp), 1000Genomes rs746679033, ExAC rs746679033, TOPMed rs746679033, gnomAD rs746679033, REVEL 0.35, CADD 17.20
- G17S (p.Gly17Ser), TOPMed rs1907106036, REVEL 0.26, CADD 14.10
- G17V (p.Gly17Val), 1000Genomes rs746679033, ExAC rs746679033, TOPMed rs746679033, gnomAD rs746679033, REVEL 0.34, CADD 16.80
- G18D (p.Gly18Asp), TOPMed rs1162126966, gnomAD rs1162126966, REVEL 0.34, CADD 17.30
- G18S (p.Gly18Ser), ExAC rs777458734, gnomAD rs777458734, REVEL 0.14, CADD 5.97
- G18V (p.Gly18Val), TOPMed rs1162126966, gnomAD rs1162126966, REVEL 0.35, CADD 17.20
- G19E (p.Gly19Glu), TOPMed rs1907105346, gnomAD rs1907105346, REVEL 0.32, CADD 18.30
- G19R (p.Gly19Arg), ExAC rs758748023, TOPMed rs758748023, gnomAD rs758748023, REVEL 0.36, CADD 10.10
- G20A (p.Gly20Ala), Ensembl rs2144573180
- G21S (p.Gly21Ser), 1000Genomes rs572820835, ExAC rs572820835, TOPMed rs572820835, gnomAD rs572820835, REVEL 0.21, CADD 1.58
- L22M (p.Leu22Met), ExAC rs754349218, gnomAD rs754349218, REVEL 0.18, CADD 0.81
- L22R (p.Leu22Arg), Ensembl rs2144573158
- G23A (p.Gly23Ala), gnomAD rs1449785246
- G23D (p.Gly23Asp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- G23V (p.Gly23Val), gnomAD rs1449785246, REVEL 0.21, CADD 16.30
- S24G (p.Ser24Gly), ExAC rs760809930, gnomAD rs760809930, REVEL 0.22, CADD 0.81
- S24I (p.Ser24Ile), ExAC rs750662716, TOPMed rs750662716, gnomAD rs750662716, REVEL 0.21, CADD 14.20
- S24N (p.Ser24Asn), ExAC rs750662716, TOPMed rs750662716, gnomAD rs750662716, REVEL 0.18, CADD 13.10
- S24R (p.Ser24Arg), 1000Genomes rs369925340, ESP rs369925340, ExAC rs369925340, TOPMed rs369925340, REVEL 0.27, CADD 0.00, Likely benign
- G25R (p.Gly25Arg), rs762726903, NCI-TCGA Cosmic COSV5585, ExAC rs762726903, gnomAD rs762726903, REVEL 0.22, CADD 9.45, Variant assessed as somatic; moderate impact.
- G26D (p.Gly26Asp), ExAC rs775365716, gnomAD rs775365716, REVEL 0.26, CADD 5.56
- G26S (p.Gly26Ser), gnomAD rs1310435573, REVEL 0.18, CADD 6.34
- S27R (p.Ser27Arg), Ensembl rs1907103921
- I28K (p.Ile28Lys), Ensembl rs1473727726, REVEL 0.34, CADD 3.59
- Y32C (p.Tyr32Cys), rs776515706, ClinGen CA8562325, ClinVar RCV002769216, ExAC rs776515706, REVEL 0.30, CADD 0.36, Uncertain significance, Inborn genetic diseases
- S33I (p.Ser33Ile), ExAC rs770476129, TOPMed rs770476129, gnomAD rs770476129, REVEL 0.37, CADD 18.40
- S33R (p.Ser33Arg), ExAC rs746512534, gnomAD rs746512534, REVEL 0.35, CADD 4.67
- R34C (p.Arg34Cys), ESP rs376754002, ExAC rs376754002, TOPMed rs376754002, gnomAD rs376754002, REVEL 0.28, CADD 14.40
- R34H (p.Arg34His), rs146238717, ClinGen CA8562320, ClinVar RCV003342395, 1000Genomes rs146238717, REVEL 0.14, CADD 13.80, Uncertain significance, Inborn genetic diseases
- R34L (p.Arg34Leu), 1000Genomes rs146238717, ESP rs146238717, ExAC rs146238717, TOPMed rs146238717, REVEL 0.20, CADD 13.50, Uncertain significance
- S36R (p.Ser36Arg), TOPMed rs1428838375
- S36T (p.Ser36Thr), gnomAD rs1452186640, REVEL 0.18, CADD 13.20
- S37F (p.Ser37Phe), ExAC rs779444299, TOPMed rs779444299, gnomAD rs779444299, REVEL 0.28, CADD 16.70
- S38L (p.Ser38Leu), gnomAD rs1488084404
- G39R (p.Gly39Arg), 1000Genomes rs556615807, ExAC rs556615807, gnomAD rs556615807, REVEL 0.32, CADD 7.95
- G40D (p.Gly40Asp), ExAC rs750515556, TOPMed rs750515556, gnomAD rs750515556, REVEL 0.48, CADD 17.40
- G41S (p.Gly41Ser), rs201530335, ClinGen CA8562312, ClinVar RCV001127350, 1000Genomes rs201530335, REVEL 0.36, CADD 2.78, Uncertain significance, Palmoplantar keratoderma, epidermolytic
- G41V (p.Gly41Val), Ensembl rs1907101558
- G42R (p.Gly42Arg), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- G43* (p.Gly43Ter), NCI-TCGA Cosmic COSV9987, CADD 32.00, Variant assessed as somatic; high impact.
- G43E (p.Gly43Glu), Ensembl rs1597794890, REVEL 0.42, CADD 21.20
- G43R (p.Gly43Arg), gnomAD rs1270637236, REVEL 0.30, CADD 13.20
- G44R (p.Gly44Arg), ExAC rs751689762, TOPMed rs751689762, gnomAD rs751689762, REVEL 0.50, CADD 23.00
- G44W (p.Gly44Trp), ExAC rs751689762, TOPMed rs751689762, gnomAD rs751689762
- G45D (p.Gly45Asp), gnomAD rs1319900683
- G45S (p.Gly45Ser), gnomAD rs1360738407, REVEL 0.38, CADD 20.60
- R46* (p.Arg46Ter), 1000Genomes rs546893755, ExAC rs546893755, gnomAD rs546893755, CADD 33.00
- R46G (p.Arg46Gly), 1000Genomes rs546893755, ExAC rs546893755, gnomAD rs546893755
- R46Q (p.Arg46Gln), rs759302830, NCI-TCGA Cosmic COSV5585, ExAC rs759302830, REVEL 0.33, CADD 16.30, Variant assessed as somatic; moderate impact.
- S49F (p.Ser49Phe), ExAC rs776605756, TOPMed rs776605756, gnomAD rs776605756, REVEL 0.35, CADD 23.50
- S50P (p.Ser50Pro), ExAC rs770850350, gnomAD rs770850350, REVEL 0.41, CADD 22.90
- S51C (p.Ser51Cys), NCI-TCGA Cosmic COSV9987, REVEL 0.19, CADD 14.70, Variant assessed as somatic; moderate impact.
- S51G (p.Ser51Gly), Ensembl rs1907100574
- S51I (p.Ser51Ile), NCI-TCGA TCGA novel, Ensembl rs1907100477, Variant assessed as somatic; moderate impact.
- G52D (p.Gly52Asp), gnomAD rs1421476645, REVEL 0.44, CADD 18.10
- Y53D (p.Tyr53Asp), TOPMed rs1484119263, gnomAD rs1484119263, REVEL 0.27, CADD 17.60
- Y53F (p.Tyr53Phe), TOPMed rs926641605, gnomAD rs926641605, REVEL 0.29, CADD 1.47
- Y53N (p.Tyr53Asn), NCI-TCGA Cosmic COSV5585, Variant assessed as somatic; moderate impact.
- G54S (p.Gly54Ser), TOPMed rs1907099912, REVEL 0.24, CADD 10.00
- G54V (p.Gly54Val), gnomAD rs1477566105, REVEL 0.27, CADD 11.90
- G55R (p.Gly55Arg), ExAC rs772792541, gnomAD rs772792541, REVEL 0.29, CADD 15.70
- G55W (p.Gly55Trp), rs772792541, ExAC rs772792541, gnomAD rs772792541, REVEL 0.30, CADD 22.50, Variant assessed as somatic; moderate impact.
- G56R (p.Gly56Arg), TOPMed rs1782111348, REVEL 0.35, CADD 14.60
- S57I (p.Ser57Ile), ExAC rs771435082, TOPMed rs771435082, gnomAD rs771435082, REVEL 0.27, CADD 14.90, Uncertain significance, Epidermolytic palmoplantar keratoderma, 1
- S57N (p.Ser57Asn), ExAC rs771435082, TOPMed rs771435082, gnomAD rs771435082, REVEL 0.15, CADD 13.50, Uncertain significance, Epidermolytic palmoplantar keratoderma, 1
- R59C (p.Arg59Cys), ExAC rs747867129, TOPMed rs747867129, gnomAD rs747867129, REVEL 0.35, CADD 15.70
- R59G (p.Arg59Gly), ExAC rs747867129, TOPMed rs747867129, gnomAD rs747867129, REVEL 0.44, CADD 6.84
- R59H (p.Arg59His), ExAC rs778678852, TOPMed rs778678852, gnomAD rs778678852, REVEL 0.28, CADD 13.30
- R59L (p.Arg59Leu), ExAC rs778678852, TOPMed rs778678852, gnomAD rs778678852, REVEL 0.32, CADD 16.00
- R59P (p.Arg59Pro), rs778678852, ExAC rs778678852, TOPMed rs778678852, gnomAD rs778678852, REVEL 0.47, CADD 16.50, Variant assessed as somatic; moderate impact.
- V60F (p.Val60Phe), ExAC rs769195603, TOPMed rs769195603, gnomAD rs769195603, REVEL 0.37, CADD 16.20
- V60I (p.Val60Ile), ExAC rs769195603, TOPMed rs769195603, gnomAD rs769195603, REVEL 0.09, CADD 8.81
- C61S (p.Cys61Ser), TOPMed rs1340627837, gnomAD rs1340627837, REVEL 0.20, CADD 6.31
- C61W (p.Cys61Trp), ExAC rs780777859, TOPMed rs780777859, gnomAD rs780777859, REVEL 0.49, CADD 21.70
- C61Y (p.Cys61Tyr), NCI-TCGA TCGA novel, REVEL 0.25, CADD 12.10, Variant assessed as somatic; moderate impact.
- G62V (p.Gly62Val), ExAC rs756652267, gnomAD rs756652267, REVEL 0.46, CADD 17.90
- R63K (p.Arg63Lys), NCI-TCGA Cosmic COSV5585, Variant assessed as somatic; moderate impact.
- G64V (p.Gly64Val), TOPMed rs1339568727, gnomAD rs1339568727, REVEL 0.53, CADD 18.10
- G65D (p.Gly65Asp), gnomAD rs1470857969, REVEL 0.44, CADD 18.90
- G66C (p.Gly66Cys), ExAC rs757250510, gnomAD rs757250510, REVEL 0.25, CADD 20.60, Uncertain significance
- G66S (p.Gly66Ser), rs757250510, ClinGen CA8562295, ClinVar RCV002830619, ExAC rs757250510, REVEL 0.19, CADD 8.84, Uncertain significance, Inborn genetic diseases
- G67S (p.Gly67Ser), gnomAD rs1465106739, REVEL 0.28, CADD 0.10
- S68N (p.Ser68Asn), ESP rs369258653, ExAC rs369258653, TOPMed rs369258653, gnomAD rs369258653, REVEL 0.18, CADD 2.24
- Y71C (p.Tyr71Cys), rs1350886851, ClinGen CA399503108, ClinVar RCV001127349, gnomAD rs1350886851, REVEL 0.28, CADD 13.50, Uncertain significance, Palmoplantar keratoderma, epidermolytic
- Y71H (p.Tyr71His), NCI-TCGA Cosmic COSV5585, Variant assessed as somatic; moderate impact.
- S72N (p.Ser72Asn), gnomAD rs1471930587, REVEL 0.24, CADD 9.39
- Y73* (p.Tyr73Ter), ExAC rs754832375, TOPMed rs754832375, gnomAD rs754832375
- G74C (p.Gly74Cys), TOPMed rs1188648638, gnomAD rs1188648638, REVEL 0.28, CADD 11.80, Uncertain significance, Inborn genetic diseases
- G74D (p.Gly74Asp), NCI-TCGA Cosmic COSV5585, TOPMed rs1907096227, gnomAD rs1907096227, REVEL 0.39, CADD 16.80, Variant assessed as somatic; moderate impact.
- G74R (p.Gly74Arg), TOPMed rs1188648638, gnomAD rs1188648638, REVEL 0.44, CADD 16.50, Uncertain significance
- G74S (p.Gly74Ser), TOPMed rs1188648638, gnomAD rs1188648638, REVEL 0.31, CADD 4.41, Uncertain significance
- G75* (p.Gly75Ter), ESP rs143561490, ExAC rs143561490, TOPMed rs143561490, gnomAD rs143561490, Uncertain significance
- G75E (p.Gly75Glu), 1000Genomes rs114289459, ESP rs114289459, ExAC rs114289459, TOPMed rs114289459, REVEL 0.46, CADD 14.80, Uncertain significance, Inborn genetic diseases
- G75R (p.Gly75Arg), rs143561490, ClinGen CA8562288, ClinVar RCV003207367, ESP rs143561490, REVEL 0.42, CADD 2.02, Uncertain significance, Inborn genetic diseases
- G76* (p.Gly76Ter), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- G76E (p.Gly76Glu), rs2508722337, ClinGen CA399503016, ClinVar RCV003212733, REVEL 0.42, CADD 10.10, Uncertain significance, Inborn genetic diseases
- G76R (p.Gly76Arg), rs1317930682, TOPMed rs1317930682, gnomAD rs1317930682, REVEL 0.38, CADD 11.20, Variant assessed as somatic; moderate impact.
- S77P (p.Ser77Pro), TOPMed rs1907095049, REVEL 0.32, CADD 8.94
- G78V (p.Gly78Val), ExAC rs774207090
- G79D (p.Gly79Asp), Ensembl rs898333521, REVEL 0.47, CADD 22.30
- F81I (p.Phe81Ile), TOPMed rs1478868415, gnomAD rs1478868415, REVEL 0.21, CADD 15.40
- F81L (p.Phe81Leu), TOPMed rs1907094125
- F81V (p.Phe81Val), TOPMed rs1478868415, gnomAD rs1478868415, REVEL 0.20, CADD 15.30
- S82N (p.Ser82Asn), rs148867398, ClinGen CA8562282, ClinVar RCV000302638, ClinVar RCV002061225, REVEL 0.25, CADD 19.70, Likely benign, Palmoplantar keratoderma, epidermolytic; not provided
- S82R (p.Ser82Arg), TOPMed rs1355171152, gnomAD rs1355171152, REVEL 0.41, CADD 6.85
- A83V (p.Ala83Val), ExAC rs776015053, gnomAD rs776015053, REVEL 0.27, CADD 1.99
- S84G (p.Ser84Gly), rs563000405, ClinGen CA8562280, NCI-TCGA Cosmic COSV5585, ClinVar RCV001126938, REVEL 0.26, CADD 7.63, Conflicting interpretations, Inborn genetic diseases; not provided; Palmoplantar keratoderma, epidermolytic
- S84I (p.Ser84Ile), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- S84R (p.Ser84Arg), 1000Genomes rs563000405, ExAC rs563000405, TOPMed rs563000405, gnomAD rs563000405, REVEL 0.45, CADD 0.21, Uncertain significance
- S85I (p.Ser85Ile), Ensembl rs1907093100
- L86S (p.Leu86Ser), Ensembl rs1907092987, REVEL 0.37, CADD 7.56
- G87R (p.Gly87Arg), ExAC rs746424414, gnomAD rs746424414, REVEL 0.48, CADD 7.18, Uncertain significance, Inborn genetic diseases
- G88D (p.Gly88Asp), Ensembl rs1452318170, REVEL 0.41, CADD 17.90
- G88S (p.Gly88Ser), ExAC rs757413698, gnomAD rs757413698, REVEL 0.33, CADD 1.80
- G89D (p.Gly89Asp), gnomAD rs1172582138, REVEL 0.43, CADD 15.80
- G89V (p.Gly89Val), gnomAD rs1172582138, REVEL 0.41, CADD 15.30
- F90S (p.Phe90Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- G91A (p.Gly91Ala), gnomAD rs1413277294, REVEL 0.38, CADD 18.40, Uncertain significance, Inborn genetic diseases
- G91E (p.Gly91Glu), NCI-TCGA Cosmic COSV9987, gnomAD rs1413277294, Variant assessed as somatic; moderate impact.
- G91R (p.Gly91Arg), TOPMed rs1403721883, gnomAD rs1403721883, REVEL 0.42, CADD 20.30, Uncertain significance, Inborn genetic diseases
- G92D (p.Gly92Asp), ExAC rs777762700, TOPMed rs777762700, gnomAD rs777762700, REVEL 0.57, CADD 21.80, Uncertain significance, Inborn genetic diseases
- G93V (p.Gly93Val), ExAC rs758632125, gnomAD rs758632125, REVEL 0.43, CADD 14.20
- S94T (p.Ser94Thr), ExAC rs752868539, TOPMed rs752868539, gnomAD rs752868539, REVEL 0.24, CADD 9.89, Uncertain significance, Inborn genetic diseases
- R95K (p.Arg95Lys), TOPMed rs1218715941, gnomAD rs1218715941, REVEL 0.28, CADD 9.16
- R95S (p.Arg95Ser), gnomAD rs1450562204, REVEL 0.38, CADD 0.10
- G96D (p.Gly96Asp), gnomAD rs945694059
- G96S (p.Gly96Ser), rs145530082, ClinGen CA8562271, ClinVar RCV000397762, ClinVar RCV002522958, REVEL 0.35, CADD 0.67, Conflicting interpretations, not provided; Inborn genetic diseases; Palmoplantar keratoderma, epidermolytic
- G96V (p.Gly96Val), gnomAD rs945694059, REVEL 0.33, CADD 15.60
- G98C (p.Gly98Cys), ExAC rs750424715, REVEL 0.47, CADD 18.20
- G98D (p.Gly98Asp), TOPMed rs914181565, gnomAD rs914181565, REVEL 0.47, CADD 20.80
- G98V (p.Gly98Val), TOPMed rs914181565, gnomAD rs914181565, REVEL 0.49, CADD 20.50
- A100V (p.Ala100Val), gnomAD rs1375408427, REVEL 0.31, CADD 3.38
- S101F (p.Ser101Phe), ESP rs368200002, ExAC rs368200002, gnomAD rs368200002, REVEL 0.46, CADD 0.65
- G102E (p.Gly102Glu), ESP rs374319007, ExAC rs374319007, TOPMed rs374319007, gnomAD rs374319007, REVEL 0.39, CADD 17.60, Uncertain significance, Inborn genetic diseases
- G103E (p.Gly103Glu), Ensembl rs1567733322, NCI-TCGA TCGA novel, REVEL 0.40, CADD 10.70, Variant assessed as somatic; high impact.
- G104C (p.Gly104Cys), TOPMed rs868735223, gnomAD rs868735223, REVEL 0.36, CADD 6.64
- G104S (p.Gly104Ser), NCI-TCGA Cosmic COSV5585, TOPMed rs868735223, gnomAD rs868735223, REVEL 0.25, CADD 3.84, Variant assessed as somatic; moderate impact.
- S106R (p.Ser106Arg), ExAC rs763644429, gnomAD rs763644429
- S107R (p.Ser107Arg), TOPMed rs1907088320, REVEL 0.41, CADD 0.01
- S108P (p.Ser108Pro), ExAC rs762723084, gnomAD rs762723084, REVEL 0.32, CADD 15.80
- G109W (p.Gly109Trp), ExAC rs775247961, gnomAD rs775247961, REVEL 0.49, CADD 18.80
- G112R (p.Gly112Arg), gnomAD rs1907087934, REVEL 0.39, CADD 13.20
- G113C (p.Gly113Cys), gnomAD rs1487836106
- G113D (p.Gly113Asp), TOPMed rs936910564, gnomAD rs936910564, REVEL 0.39, CADD 17.00
- G113V (p.Gly113Val), TOPMed rs936910564, gnomAD rs936910564
- G114S (p.Gly114Ser), TOPMed rs1266274182, REVEL 0.30, CADD 17.60
- G116C (p.Gly116Cys), TOPMed rs1907087377, gnomAD rs1907087377, REVEL 0.54, CADD 23.30
- G116D (p.Gly116Asp), rs746202552, ClinGen CA8562260, ClinVar RCV001126936, ClinVar RCV004986827, REVEL 0.51, CADD 22.90, Uncertain significance, Inborn genetic diseases; Palmoplantar keratoderma, epidermolytic
- G116R (p.Gly116Arg), NCI-TCGA TCGA novel, REVEL 0.58, CADD 23.00, Variant assessed as somatic; moderate impact.
- G116V (p.Gly116Val), ExAC rs746202552, TOPMed rs746202552, gnomAD rs746202552, REVEL 0.52, CADD 22.50, Uncertain significance
- G117S (p.Gly117Ser), rs372005664, ClinGen CA8562259, ClinVar RCV002682954, ESP rs372005664, REVEL 0.31, CADD 15.70, Uncertain significance, Inborn genetic diseases
- G118A (p.Gly118Ala), TOPMed rs1434499651, REVEL 0.33, CADD 9.60
- G118C (p.Gly118Cys), TOPMed rs1217003781, gnomAD rs1217003781, REVEL 0.37, CADD 17.80
Public KRT9 analysis runs
- KRT9 analysis run — KRT9 (1,176 variants) — completed 2026-08-22